title: GALECTIN-3 AS A PREDICTOR OF STATIN TREATMENT EFFICACY IN PATIENTS WITH MULTIPLE MYELOMA.
abstract: to investigate an interrelationship between pre-treatment galcetin-3 (Gal-3) level and one-year survival rate, cardiovascular events in subjects with multiple myeloma. Eighty nine subjects with full or partial remission of multiple myeloma were enrolled in the study. Patients were divided into 2 groups based on whether or not statins were included in their treatment: a statin group (n=43) and a no statin group (n=46). Among the 43 patients in the statin group, 31 patients received 20mg/day atorvastatin and 12 patients received 40-mg/day atorvastatin. None of the patients had received any lipid-modulating medications, including statins or fibrates, before enrollment. Observation period was up to 1 year. Blood samples for biomarkers measurements were collected. ELISA method for measurements of circulating level of galectin-3, interleukin-6 and NT-pro-brain natriuretic peptide were used. Lipid lowering effect in statin user was associates with declined serum Gal-3 level, whereas in not statin users similar response was not appeared. No any changes in hemodynamics and other biomarkers between both cohorts were found. Univariate logistic regression had exhibited that galtctin-3 (odds ratio [OR] = 1.17; 95% CI = 1.07-1.29; P = 0.002), NT-pro-brain natriuretic peptide (OR=1.04; 95% CI=1.02-1.10; P<0.05) and statin therapy (OR=1.07; 95% CI = 1.02-1.11; P = 0.001) predicted one-year cumulative CV events. After adjustment on statin therapy, galectin-3 remained independent predictor one-year cumulative cardiovascular events (OR=1.08; 95% CI=1.06-1.11; P=0.001). When initial serum galectin-3 level has incorporated into prediction model, statin therapy was found as predictor for improving survival in multiple myeloma patients with elevated serum galectin-3 level (>14 ng/ml). Elevated pre-treatment galectin-3 level was found a powerful predictor of positive effect of statins on survival in patients with regression of multiple myeloma.
authors.affiliation: Zaporozhye State Medical University, Zaporozhye, Ukraine.
authors.forename: B
authors.initials: B
authors.lastname: Samura
mesh_terms: D000069059:Atorvastatin / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D050171:Dyslipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D005260:Female; D037502:Galectin 3 / Q000378:metabolism*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D037502:Galectin 3; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000069059:Atorvastatin